NEW YORK / Mar 04, 2024 / Business Wire / MultiPlan Corporation (NYSE:MPLN) (“MultiPlan” or the “Company”), a leading provider of technology and data-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry, today announced that members of its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 12, 2024 at approximately 3:05 p.m. Eastern Daylight Time (EDT).
To listen to a live webcast of the event, please visit MultiPlan’s website at https://investors.multiplan.us/events-and-presentations/default.aspx at least 15 minutes prior to the event to download and install any necessary audio software. Individuals who listen to the event will be presumed to have read MultiPlan’s recent filings with the Securities and Exchange Commission. Following the presentation, a webcast replay will be available for 30 days.
About MultiPlan
MultiPlan is committed to delivering affordability, efficiency, and fairness to the US healthcare system by helping healthcare payors manage the cost of care, improve their competitiveness and inspire positive change. Leveraging sophisticated technology, data analytics and a team rich with industry experience, MultiPlan interprets customers’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based and analytics-based, and data and decision science services. MultiPlan is a trusted partner to over 700 healthcare payors, brokers, employer groups, and supplemental carriers in the commercial health, government, and property and casualty markets. For more information, visit multiplan.com.
Last Trade: | US$6.45 |
Daily Change: | 1.24 23.80 |
Daily Volume: | 138,164 |
Market Cap: | US$104.300M |
November 05, 2024 October 03, 2024 May 08, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB